#USA #San Diego #Cancer Monitoring #SeekInClarity #multi-omics test

A Breakthrough in Cancer Treatment Monitoring: SeekInClarity's Multi-Omics Test

In a groundbreaking study published in BMC Cancer, SeekInClarity unveils a novel blood-based multi-omics test that is set to transform the landscape of cancer treatment monitoring, particularly for lymphoma patients. This test integrates genomic, epigenetic, and proteomic data from blood samples, providing an accurate and non-invasive alternative to traditional imaging methods for assessing treatment responses.

The Study's Promising Findings

The prospective study involved 116 newly diagnosed lymphoma patients across various subtypes, demonstrating a significant correlation between the molecular tumor burden (MTB) score derived from SeekInClarity and advanced tumor stages. Patients with consistently positive MTB statuses after two treatment cycles exhibited substantially poorer progression-free and overall survival rates. This relationship highlights the test's potential as a reliable predictor of therapeutic outcomes.

Furthermore, the SeekInClarity multi-omics approach outperformed established clinical biomarkers, such as B2M and LDH, as the primary independent indicators of treatment success. This compelling evidence illustrates how molecular responses measured by SeekInClarity and interim PET/CT scans are vital for accurate risk stratification in patients undergoing treatment.

Importance of Non-Invasive Testing

Current monitoring practices heavily rely on conventional imaging techniques like PET-CT or CT scans, which can be both expensive and limited in sensitivity. The SeekInClarity assay offers an economical solution, allowing for prompt and precise risk evaluation and enabling earlier intervention for patients unlikely to respond to standard therapies.

Dr. Mao Mao, the CEO and founder of SeekIn Inc., emphasized, "Our findings underscore the clinical value of integrating multi-omics liquid biopsy approaches like SeekInClarity into routine lymphoma management. This tool can identify high-risk patients earlier and more accurately than current methods, guiding more personalized treatment decisions." This innovative approach prioritizes the patient's needs and tailors treatment strategies accordingly.

Clinical Validation and Methodology

The study's methodology was rigorous, enrolling participants from two major cancer centers in China. Blood samples were meticulously collected before the initiation of treatment and after two cycles, assessing the changes in the MTB score and validating the results against interim PET/CT imaging and standard clinical biomarkers. The robust predictive power of SeekInClarity's molecular response framework emerged notably in cases of aggressive B-cell and NK/T-cell lymphomas, setting a new standard for treatment monitoring.

The Future of Cancer Monitoring

SeekInClarity's promising results pave the way for wider integration of blood-based multi-omics monitoring in lymphoma treatments and potentially in the management of other cancers. This innovative tool empowers clinicians to optimize patient outcomes, ensuring that therapies are effectively tailored to meet each patient's unique cancer profile.

By advancing into clinical practice, the SeekInClarity test could revolutionize how cancer treatment responses are assessed, significantly impacting patient care and survival rates. As the study reveals, early detection and proper monitoring are crucial steps in combating cancer effectively.

About SeekInClarity

Developed by SeekIn Inc., SeekInClarity is designed as a comprehensive, blood-based pan-cancer and pan-indication test for monitoring treatment responses across various cancers. Leveraging sophisticated algorithms, SeekInClarity assesses therapeutic efficacy through multivariable analyses, delivering real-time predictions regarding tumor burden and treatment responses. The test's performance was validated by regulatory bodies, receiving the CE-IVD mark in May 2022, confirming its applicability across clinical settings.

Conclusion

With SeekInClarity, the future holds great promise for more effective cancer treatment monitoring. The integration of such advanced technologies not only enhances the accuracy of predicting treatment outcomes but also contributes positively to the overall journey of cancer patients embarking on their fight against this formidable disease.